Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.53 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.48 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
| ▸ | GPR17 | Q13304 | 3/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16777344 | 1.00 | POLA1 (0.53) | POLA1P2RY1P2RX3P2RX1ENPP1 | |
| SCHEMBL16777519 | 0.92 | P2RY1 (0.49) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL17617926 | 0.91 | P2RY1 (0.49) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL16776967 | 0.90 | POLA1 (0.56) | POLA1P2RY1P2RX3P2RX1ENPP1 | |
| SCHEMBL16777770 | 0.90 | POLA1 (0.56) | POLA1P2RY1P2RX3P2RX1ENPP1 | |
| SCHEMBL16777534 | 0.90 | POLA1 (0.56) | POLA1P2RY1P2RX3P2RX1ENPP1 | |
| SCHEMBL16777864 | 0.90 | POLA1 (0.56) | POLA1P2RY1P2RX3P2RX1ENPP1 | |
| SCHEMBL26025267 | 0.89 | POLA1 (0.55) | POLA1P2RY1P2RX3P2RX1ENPP1 | |
| SCHEMBL16081063 | 0.89 | P2RY1 (0.51) | P2RY1P2RX3P2RX1ENPP1P2RX4 | |
| SCHEMBL26025244 | 0.88 | GPR17 (0.53) | POLA1P2RY1P2RX3P2RX1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2015081297-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | HAVCR2, SLC29A2, SLC28A2 | POLA1 276/4885P2RY1 1177/4885P2RX3 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.